The combination of Keytruda (pembrolizumab) and Welireg (belzutifan) improved disease-free survival compared with Keytruda ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Because both Opdivo and Keytruda are approved to treat certain types of cancer, you may be able to switch from one drug to the other. Depending on the cancer being treated, there may be specific ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...